Background Nivolumab is an anti–PD-1 antibody that restores the antitumour immune function of T cells, blocking the binding of PD-1 with its ligand PD-L1. PD-1 is expressed on T cells and interacts with PD-L1 on tumour cells. The PD-1–PD-L1 link inhibits T cell activation. In metastatic melanoma, PD-1–PD-L1 binding plays a critical role, and the advent of the immune checkpoint inhibitor nivolumab has delivered new and effective treatment options with proven clinical benefit. In the present study, we evaluated the efficacy of nivolumab in elderly patients with metastatic melanoma. Methods The study enrolled 55 elderly patients (75 years of age and older) with a diagnosis of metastatic melanoma. Primary endpoints of the study were progression-free survival (pfs) and the objective response rate; secondary endpoints were overall survival, reduction in serum lactate dehydrogenase (ldh) from before to after treatment, and tolerability. Results Nivolumab was well tolerated and resulted in good disease control, with a manageable toxicity profile and significant clinical benefit. The duration of pfs was 5.1 months (95% confidence interval: 3.5 months to 6.8 months). A significant correlation was observed between reduction in serum ldh and pfs: 0.60 (95% confidence interval: 0.28 to 0.86; p = 0.002). Conclusions Nivolumab is an immunotherapy treatment that has proved to be an effective and well-tolerated therapeutic option in elderly patients with metastatic melanoma. Key Words Nivolumab; melanoma, metastatic; elderly patients; immunotherapy; quality of life; clinical benefit; lactate dehydrogenase

Rossella De Luca, S.M. (2020). Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients. CURRENT ONCOLOGY, 27(2), e75-e80 [10.3747/co.27.5293].

Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients

Rossella De Luca;Serena Meraviglia;
2020

Abstract

Background Nivolumab is an anti–PD-1 antibody that restores the antitumour immune function of T cells, blocking the binding of PD-1 with its ligand PD-L1. PD-1 is expressed on T cells and interacts with PD-L1 on tumour cells. The PD-1–PD-L1 link inhibits T cell activation. In metastatic melanoma, PD-1–PD-L1 binding plays a critical role, and the advent of the immune checkpoint inhibitor nivolumab has delivered new and effective treatment options with proven clinical benefit. In the present study, we evaluated the efficacy of nivolumab in elderly patients with metastatic melanoma. Methods The study enrolled 55 elderly patients (75 years of age and older) with a diagnosis of metastatic melanoma. Primary endpoints of the study were progression-free survival (pfs) and the objective response rate; secondary endpoints were overall survival, reduction in serum lactate dehydrogenase (ldh) from before to after treatment, and tolerability. Results Nivolumab was well tolerated and resulted in good disease control, with a manageable toxicity profile and significant clinical benefit. The duration of pfs was 5.1 months (95% confidence interval: 3.5 months to 6.8 months). A significant correlation was observed between reduction in serum ldh and pfs: 0.60 (95% confidence interval: 0.28 to 0.86; p = 0.002). Conclusions Nivolumab is an immunotherapy treatment that has proved to be an effective and well-tolerated therapeutic option in elderly patients with metastatic melanoma. Key Words Nivolumab; melanoma, metastatic; elderly patients; immunotherapy; quality of life; clinical benefit; lactate dehydrogenase
Rossella De Luca, S.M. (2020). Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients. CURRENT ONCOLOGY, 27(2), e75-e80 [10.3747/co.27.5293].
File in questo prodotto:
File Dimensione Formato  
nivo.pdf

non disponibili

Tipologia: Post-print
Dimensione 226.98 kB
Formato Adobe PDF
226.98 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/431402
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 3
social impact